Built on Purpose, Growing with Heart CINCINNATI, OH / ACCESS Newswire / June 3, 2025 / In just one year, AcutePet Urgent Care ...

Sanofi announced today that the U.S. FDA has granted orphan drug designation to rilzabrutinib for the treatment of sickle ...

MUNICH, GERMANY AND LONDON, UK / ACCESS Newswire / June 3, 2025 / Infineon Technologies AG, a world leader in semiconductor solutions, today announced a strategic partnership with The Healthcare ...

Longevity Method, a leader in advanced health and wellness solutions, announces the launch of Live Longer - NMN+, a revolutionary NMN supplement designed to enhance cellular health and combat ...

Notice to convene extraordinary GENERAL MEETING REGARDING EXTRAORDINARY DIVIDENDGUBRA A/SCVR NO. 30 51 40 41To the shareholders of Gubra A/S (CVR no. 30 51 40 41), notice is hereby given to convene an ...

One-year follow-up data from first-in-human trial shows significant improvements in key clinical performance outcomes This data supports a strong safety profile for the VCFix® Spinal System for the ...

The Global Hyperbaric Oxygen Therapy Devices Market is expected to grow at a rate of 6.5% by 2026.Growing number of acute and chronic infections, adoption of HBOT in cosmetic procedures and wound ...

The need for laparoscopic devices is predicted to rise at a sluggish CAGR of 4.2% through 2034. The industry is projected to surpass USD 20.5 billion by 2034. The surge in the prevalence of obesity ...

The Global Vaccine Storage Equipment Market is expected to grow at a rate of 8-10% by 2026. Rising number of infectious diseases and immunological disorders, large-scale implementation of vaccination ...

The global sales of rare neurological disease treatment is estimated to be worth USD 19.95 billion in 2025 and anticipated to reach a value of USD 40.67 billion by 2035. Sales are projected to rise at ...

The Rare Inflammatory Disease Treatment Market has garnered a market value of USD 12,664 Million in 2021, anticipated to register a positive CAGR of 4.6% in the forecast period 2022 to 2028 and reach ...

Simris Group AB (publ), through its wholly owned subsidiary Simris Biologics GmbH, has signed a non-binding concept sheet with a EU based biopharmaceutical company specializing in the development of ...